Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies.
about
Effects of messenger RNA structure and other translational control mechanisms on major histocompatibility complex-I mediated antigen presentationTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaVirus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaEpstein-Barr virus associated modulation of Wnt pathway is not dependent on latent membrane protein-1.Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells.Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma.Epstein-Barr virus-associated lymphomas.The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.Association between interferon gamma 13-CA-repeats polymorphism and metastasis of nasopharyngeal carcinoma in a population of Northern China.Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response.Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes.The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphomaRegulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition.Identifying novel genes and chemicals related to nasopharyngeal cancer in a heterogeneous network.Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppressionCurrent understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.Epstein-Barr virus: novel patented therapeutics.Immunotherapy for epstein-barr virus-related lymphomas.T-cell therapy in the treatment of post-transplant lymphoproliferative diseaseThe Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1.Tumor-specific immune responses.Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopesEpstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty?Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders.
P2860
Q26852540-9DFF66CB-E66C-45E3-A624-FFD9F94871FEQ27016002-D953BE45-BDED-49D9-831F-D13E17EE897EQ29622835-369DCD4D-0474-4972-A626-B157C92700F2Q33370930-82E5FED9-DA3F-4CBD-8124-6CC0AF49D65CQ34180551-6FA690BD-31B5-4231-AF25-B345B9DE6167Q34317937-3E02F7E0-EB46-428F-B829-B1B8C8AF40FEQ34353696-B2E4F6B6-8AAA-4E96-BCD3-C89C40ED9940Q34619694-006260B5-970E-4480-BE6C-0DB8F68292BAQ34651670-08405DE2-9DF6-4D37-B19D-1D0A7E36DD35Q35000726-1DEC93EF-6ADA-48AB-8F1A-D0FBC1C3C966Q35919485-917330CB-424A-403D-BC7C-F31325E0078EQ36099296-7B5FD43D-5107-416F-83DA-90CC9CD37CA1Q36241068-78F7B001-E9DC-4522-8459-7A81B357DA6FQ36267161-7E2203EB-2862-41AF-838D-6FAA8E96794CQ36457849-4DBABAE8-BDB4-4416-ACC5-DAEC7810D82CQ36756835-1C3076CB-3796-4298-B21E-0644B6410F90Q36872700-37D58E4E-CBF0-4C1D-80B3-E46F5B9E44B7Q37204614-4E0A6958-FCA1-4019-8E3A-9D55A2FDFB7FQ37280924-C75CEC38-2C4A-44FA-845C-C13C20081C86Q37729167-DE447BAB-0DD4-4F05-B869-80E13D4953AFQ37854471-EDA7D671-EBC6-4882-97B0-5AC789761B27Q38026758-BB55CBEC-AF2C-4FF3-82DF-96C33DD17519Q40134553-70F5D281-5BA5-4BF8-A274-E22527B4B008Q40398766-9AA1149B-B2DD-4EFA-BDBF-5EAB7AA41F3EQ42027228-250AF164-0292-498D-9D7E-DF55D257727DQ45415979-B2D6A7DA-14B2-45A1-9EB4-8D1B1E10292DQ53560320-8CB258D5-A75A-4B15-9758-4DE5D2851DB0
P2860
Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Technology insight: Applicatio ...... virus-associated malignancies.
@ast
Technology insight: Applicatio ...... virus-associated malignancies.
@en
type
label
Technology insight: Applicatio ...... virus-associated malignancies.
@ast
Technology insight: Applicatio ...... virus-associated malignancies.
@en
prefLabel
Technology insight: Applicatio ...... virus-associated malignancies.
@ast
Technology insight: Applicatio ...... virus-associated malignancies.
@en
P2093
P2860
P356
P1476
Technology insight: Applicatio ...... virus-associated malignancies.
@en
P2093
Denis Moss
Maher Gandhi
Rajiv Khanna
P2860
P2888
P304
P356
10.1038/NCPONC0107
P577
2005-03-01T00:00:00Z
P6179
1018646620